TWI734047B - Light care system and light care method - Google Patents
Light care system and light care method Download PDFInfo
- Publication number
- TWI734047B TWI734047B TW107140149A TW107140149A TWI734047B TW I734047 B TWI734047 B TW I734047B TW 107140149 A TW107140149 A TW 107140149A TW 107140149 A TW107140149 A TW 107140149A TW I734047 B TWI734047 B TW I734047B
- Authority
- TW
- Taiwan
- Prior art keywords
- light
- user
- item
- physiological data
- physiological
- Prior art date
Links
Images
Landscapes
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Length Measuring Devices By Optical Means (AREA)
- Measurement Of Optical Distance (AREA)
Abstract
Description
本揭露是有關於一種照護系統以及照護方法,且特別是有關於一種光照護系統以及光照護方法。The present disclosure relates to a care system and a care method, and particularly relates to a light care system and a light care method.
根據研究結果顯示,國內外約有1/4至1/5的人有情緒問題或睡眠問題。情緒問題(如憂鬱症)可能成為醫療保健的最重負擔,而睡眠問題可能對情緒、壓力、心臟或代謝產生負面影響。目前,主要採取藥物治療來解決患者的情緒問題及睡眠問題。然而,有38%的藥物治療對憂鬱症是無效的。此外,藥物通常會造成副作用,例如有可能導致患者對於身體的控制能力降低、引發其他疾病或增加死亡率等。另外,藥物有可能與食物產生交互作用,而導致副作用出現、人體分解藥物速度降低或毒素的產生。因此,採取藥物治療容易造成飲食的不便。According to research results, about 1/4 to 1/5 of people at home and abroad have emotional problems or sleep problems. Emotional problems (such as depression) may become the heaviest burden of medical care, and sleep problems may have a negative impact on mood, stress, heart, or metabolism. At present, medication is mainly used to solve the emotional problems and sleep problems of patients. However, 38% of drug treatments are ineffective for depression. In addition, drugs often cause side effects, such as reducing the patient's ability to control the body, causing other diseases, or increasing mortality. In addition, drugs may interact with food, which may lead to side effects, slower decomposition of drugs by the body, or production of toxins. Therefore, taking medication can easily cause dietary inconvenience.
本揭露提供一種光照護系統以及光照護方法,其可在較小副作用且飲食較不受限的前提下有效改善、紀錄與追蹤情緒問題或睡眠問題。The present disclosure provides a light protection system and a light protection method, which can effectively improve, record and track emotional problems or sleep problems under the premise of less side effects and less restricted diet.
本揭露的一實施例的光照護系統包括生理感測裝置、處理器以及光源裝置。生理感測裝置適於獲取使用者的生理數據。處理器與生理感測裝置耦接,且處理器依據生理數據獲取對應生理數據的至少一光參數。光源裝置與處理器耦接,且光源裝置依據所述至少一光參數輸出光束,其中光束中的綠光或藍光佔光束的40%以上。The light protection system of an embodiment of the present disclosure includes a physiological sensing device, a processor, and a light source device. The physiological sensing device is suitable for acquiring physiological data of the user. The processor is coupled with the physiological sensing device, and the processor obtains at least one light parameter corresponding to the physiological data according to the physiological data. The light source device is coupled to the processor, and the light source device outputs a light beam according to the at least one light parameter, wherein the green light or the blue light in the light beam occupies more than 40% of the light beam.
本揭露的一實施例的光照護方法包括步驟如下。獲取使用者的生理數據。依據生理數據獲取對應生理數據的至少一光參數。依據所述至少一光參數輸出光束,其中光束中的綠光或藍光佔光束的40%以上。The light protection method of an embodiment of the present disclosure includes the following steps. Obtain the user's physiological data. At least one light parameter corresponding to the physiological data is acquired according to the physiological data. The light beam is output according to the at least one light parameter, wherein the green light or the blue light in the light beam accounts for more than 40% of the light beam.
為讓本揭露的上述特徵和優點能更明顯易懂,下文特舉實施例,並配合所附圖式作詳細說明如下。In order to make the above-mentioned features and advantages of the present disclosure more obvious and understandable, the following specific embodiments are described in detail in conjunction with the accompanying drawings.
實施方式中所提到的方向用語,例如:「上」、「下」、「前」、「後」、「左」、「右」等,僅是參考附圖的方向。因此,使用的方向用語是用來說明,而並非用來限制本發明。在附圖中,各圖式繪示的是特定示範實施例中所使用的方法、結構及/或材料的通常性特徵。然而,這些圖式不應被解釋為界定或限制由這些示範實施例所涵蓋的範圍或性質。舉例來說,為了清楚起見,各膜層、區域及/或結構的相對厚度及位置可能縮小或放大。The directional terms mentioned in the embodiments, for example: "up", "down", "front", "rear", "left", "right", etc., are only directions with reference to the drawings. Therefore, the directional terms used are used to illustrate, but not to limit the present invention. In the drawings, each drawing depicts the general features of the methods, structures, and/or materials used in specific exemplary embodiments. However, these drawings should not be construed as defining or limiting the scope or nature covered by these exemplary embodiments. For example, for clarity, the relative thickness and position of each layer, region, and/or structure may be reduced or enlarged.
圖1是依照本揭露的一實施例的一種光照護系統的示意圖。請參照圖1,光照護系統1包括生理感測裝置10、處理器12以及光源裝置14。Fig. 1 is a schematic diagram of a light protection system according to an embodiment of the present disclosure. Please refer to FIG. 1, the
生理感測裝置10適於獲取使用者U1的生理數據BD。舉例來說,生理感測裝置10可包括腦波感測裝置、心電感測裝置、動態感測裝置、呼吸感測裝置或以上至少兩種的組合。對應地,生理數據BD可包括腦電、心律(heart rate)、心率變異分析(Heart Rate Variability, HRV)、身體位置變化量、呼吸頻率或以上至少兩種的組合。The
圖2是腦波感測裝置的一種示意圖。請參照圖2,圖1的生理感測裝置10可以是如圖2所示的腦波感測裝置10A。腦波感測裝置10A設置在使用者U1的頭上,以獲取使用者U1的腦電圖。應說明的是,圖2所示的腦波感測裝置10A僅是腦波感測裝置的其中一種實施型態,但腦波感測裝置的具體型態可依需求改變,而不以圖2所顯示的為限。Fig. 2 is a schematic diagram of a brain wave sensing device. Please refer to FIG. 2, the
圖3是獲取腦電圖時電極配置的示意圖。請參照圖3,在獲取使用者U1的腦電圖時,使用者U1的頭上以及雙耳(區域A1、A2處)上會配置成對電極,以記錄大腦皮層上額葉區(包括區域Fp1、Fp2、F3、F4、Fz、F7、F8)、顳葉區(包括區域T3、T4、T5、T6)、頂葉區(包括區域P3、P4、Pz)、枕葉區(包括區域O1、O2)以及中央溝區(包括區域C3、C4、Cz)的腦波指標。腦波指標可包括δ波、θ波、α波、β波以及γ波的其中至少一個,但不以此為限。Fig. 3 is a schematic diagram of electrode configuration when acquiring an EEG. Please refer to Figure 3, when the user U1's EEG is obtained, a pair of electrodes will be arranged on the user U1's head and both ears (areas A1 and A2) to record the upper frontal area of the cerebral cortex (including the area Fp1). , Fp2, F3, F4, Fz, F7, F8), temporal lobe area (including area T3, T4, T5, T6), parietal area (including area P3, P4, Pz), occipital area (including area O1, O2) and brain wave indicators in the central sulcus area (including areas C3, C4, and Cz). The brain wave index may include at least one of delta wave, theta wave, alpha wave, beta wave, and gamma wave, but is not limited to this.
不同的腦波指標指示人體不同的狀態。因此,藉由腦電圖觀察使用者U1的大腦皮層上至少一區的至少一腦波指標,可知曉使用者U1的狀態,例如情緒狀態、精神狀態或睡眠狀態等。此處,情緒狀態泛指使用者U1心理或生理的感受,例如放鬆的、愉悅的、活力的、專注的、清醒的或以上至少兩者的組合,但不以此為限。精神狀態泛指精神治療議題,例如憂鬱症(Depression)、季節性情緒失調(Seasonal Affective Disorder, SAD)、焦慮症(Generalized anxiety disorder, GAD)、阿茲海默症(Alzheimer's disease, AD)、帕金森氏症(Parkinson's disease, PD)或注意力不足過動症(Attention Deficit Hyperactivity Disorder, ADHD)等精神方面的問題,但不以此為限。睡眠狀態泛指睡眠品質議題以及睡眠相位議題。睡眠品質議題可包括縮短入睡時間、降低醒來次數、增加總睡眠時間、提升睡眠效率或舒緩失眠(insomnia)等,但不以此為限。睡眠相位議題可包括睡眠相位延遲(Delayed Sleep Phase Disorder, DSPD)、睡眠相位提前(Advanced Sleep Phase Disorder, ASPD)、輪班(Shift Work Disorder, SWD)或時差(jet lag)等議題。Different brain wave indicators indicate different states of the human body. Therefore, by observing at least one brain wave index in at least one area on the cerebral cortex of the user U1 through the EEG, the state of the user U1, such as the emotional state, the mental state, or the sleep state, can be known. Here, the emotional state generally refers to the psychological or physical feelings of the user U1, such as being relaxed, happy, energetic, focused, awake, or a combination of at least two of the above, but not limited to this. Mental state refers to psychiatric treatment issues, such as depression, seasonal affective disorder (SAD), generalized anxiety disorder (GAD), Alzheimer's disease (AD), and Mental problems such as Parkinson's disease (PD) or Attention Deficit Hyperactivity Disorder (ADHD), but not limited to this. Sleep state generally refers to sleep quality issues and sleep phase issues. Sleep quality issues may include shortening the time to fall asleep, reducing the number of awakenings, increasing total sleep time, improving sleep efficiency, or alleviating insomnia, but not limited to this. Sleep phase issues may include issues such as Delayed Sleep Phase Disorder (DSPD), Advanced Sleep Phase Disorder (ASPD), Shift Work Disorder (SWD), or jet lag.
圖4是心電感測裝置的一種示意圖。請參照圖4,圖1的生理感測裝置10可以是如圖4所示的心電感測裝置10B。心電感測裝置10B設置在使用者U1的手腕上,以獲取使用者U1的心律、心率變異分析或以上兩種的組合。應說明的是,圖4所示的心電感測裝置10B僅是心電感測裝置的其中一種實施型態,但心電感測裝置的具體型態可依需求改變,而不以圖4所顯示的為限。Fig. 4 is a schematic diagram of a cardiogram measuring device. Please refer to FIG. 4, the
心率變異分析可包括根據心率變異分析運算出的時域分析指標以及頻域分析指標。時域分析指標可包括正常心跳間距的標準差(Standard Deviation of Normal to Normal, SDNN),而頻域分析指標可包括低頻(Low Frequency, LF)、高頻(High Frequency, HF)以及低頻與高頻的比值(LF/HF),但不以此為限。The heart rate variability analysis may include a time domain analysis index and a frequency domain analysis index calculated according to the heart rate variability analysis. Time domain analysis indicators can include the standard deviation of normal heartbeat interval (Standard Deviation of Normal to Normal, SDNN), and frequency domain analysis indicators can include low frequency (LF), high frequency (High Frequency, HF), and low frequency and high frequency. The ratio of frequency (LF/HF), but not limited to this.
SDNN代表自律神經強弱的程度。表一示出不同年齡層所對應的SDNN。如表一所示,在正常情形下,年紀與SDNN成反比。也就是說,年紀越輕,SDNN越高;年紀越大,SDNN越弱。SDNN可以作為一個人是否未老先衰的指標,也可以作為一個患者所接受的抗疾病療程是否有效的指標。
LF是指頻率為0.040 Hz至0.150 Hz的生理電波,其是交感神經放電時的電波,代表交感神經的活性。HF是指頻率為0.15 Hz至0.400 Hz的生理電波,其是副交感神經放電時的電波,代表副交感神經的活性。LF/HF是交感神經與副交感神經活性的比值,代表自律神經活性的平衡。表二示出不同年齡層所對應的LF、HF以及LF/HF。如表二所示,21~40歲時,男性的交感(LF)高於女性,副交感(HF)則是女性高於男性。41~60歲時,男性的副交感(HF)高於女性。60歲以上的男女性,LF、HF的差異性越來越小。換句話說,LF/HF比值隨著年齡增加而下降。
請參照圖1,處理器12與生理感測裝置10耦接,且處理器12依據生理數據BD獲取對應生理數據BD的至少一光參數PM。舉例來說,處理器12可包括中央處理單元(Central Processing Unit, CPU)或圖形處理單元(Graphic Processing Unit, GPU),但不以此為限。1, the
圖5是顯示裝置的一種示意圖。請參照圖1及圖5,圖1的光照護系統1的處理器12可內建於圖5的顯示裝置DP中,但不以此為限。處理器12與生理感測裝置10可以有限或無線的方式連接,以進行訊號傳輸。處理器12可儲存、演算及分析生理數據BD,並且處理器12可依據生理數據BD(如心律、心率變異分析、腦電、身體位置變化量、呼吸頻率或以上至少兩種的組合)判斷使用者U1的睡眠狀態、情緒狀態或以上兩種的組合。在判定使用者U1的睡眠狀態、情緒狀態或以上兩種的組合後,處理器12獲取對應生理數據BD的至少一光參數PM,並將所述至少一光參數PM輸出至光源裝置14,使光源裝置14輸出對應於所述至少一光參數PM的光束LB,以藉由光束LB的照射來調整使用者U1的睡眠狀態、情緒狀態或以上兩種的組合。所述至少一光參數PM可包括照光持續時間、照光時機、照光種類、綠光佔比、藍光佔比、演色性或以上至少兩種的組合。此處,照光持續時間指的是每一次進行光照護的總時間。照光時機指的是進行光照護的使用時間點,例如睡前使用、起床後多久內使用等。照光種類包括單色光以及混光。綠光佔比指的是光束LB中的綠光佔光束LB的頻譜(spectrum)百分比。類似地,藍光佔比指的是光束LB中的藍光佔光束LB的頻譜(spectrum)百分比。Fig. 5 is a schematic diagram of a display device. 1 and 5, the
處理器12可內建有用於調整使用者U1的情緒狀態及睡眠狀態的多種演算法,而顯示裝置DP可顯示對應於不同情緒狀態及睡眠狀態的多種圖標(icons),以供使用者U1選取。在本實施例中,處理器12內建有用於調整/改善使用者U1的四種情緒狀態及四種睡眠狀態的演算法,而顯示裝置DP可顯示對應於四種情緒狀態的四種圖標(如圖標E1、E2、E3及E4)及對應於四種睡眠狀態的四種圖標(如圖標S1、S2、S3及S4)。The
舉例來說,圖標E1對應於壓力的問題。使用者U1可按下圖標E1來啟動對應的光照護功能(例如包括生理數據的獲取、儲存、演算及分析還有照光步驟),從而達到舒壓的效果。圖標E2對應於容易疲勞的問題。使用者U1可按下圖標E2來啟動對應的光照護功能,從而達到提振精神(提升活力)的效果。圖標E3對應於注意力不集中的問題。使用者U1可按下圖標E3來啟動對應的光照護功能,從而達到提升注意力的效果。圖標E4對應於心情不好及充斥負面情緒的問題。使用者U1可按下圖標E4來啟動對應的光照護功能,從而達到提升正向情緒、抑制憂鬱甚至是舒緩憂鬱症的效果。圖標S1對應於睡眠品質差的問題。睡眠品質差包括經常性入睡困難、失眠、深度睡眠不足以及總睡眠時數不足(容易醒來)等情況。使用者U1可按下圖標S1來啟動對應的光照護功能(例如包括生理數據的獲取、儲存、演算及分析還有照光步驟),從而達到改善睡眠品質的效果。圖標S2對應於睡眠相位延遲障礙(Delayed Sleep Phase Disorder, DSPD)的問題。睡眠相位延遲障礙包括凌晨2點前無法入睡且早上無法正常起床以及昏暗燈光下褪黑激素釋放(Dim Light Melatonin Onset, DLMO)的問題。使用者U1可按下圖標S2來啟動對應的光照護功能,從而達到緩解睡眠相位延遲障礙的效果。圖標S3對應於睡眠相位提前障礙(Advanced Sleep Phase Disorder, ASPD)的問題。睡眠相位提前障礙包括下午6點就想睡覺且2點左右即醒來接著就難以持續睡眠至早上以及DLMO的問題。使用者U1可按下圖標S3來啟動對應的光照護功能,從而達到緩解睡眠相位提前障礙的效果。圖標S4對應於入睡困難的問題。使用者U1可按下圖標S4來啟動對應的光照護功能,從而達到促進睡意的效果。For example, the icon E1 corresponds to the problem of stress. The user U1 can press the icon E1 to activate the corresponding light protection function (for example, including the acquisition, storage, calculation and analysis of physiological data, as well as the light step), so as to achieve the effect of relieving pressure. The icon E2 corresponds to the problem of easy fatigue. The user U1 can press the icon E2 to activate the corresponding light protection function, so as to achieve the effect of boosting energy (increasing vitality). Icon E3 corresponds to the problem of inattention. The user U1 can press the icon E3 to activate the corresponding light protection function, so as to achieve the effect of enhancing attention. Icon E4 corresponds to the problem of bad mood and full of negative emotions. The user U1 can press the icon E4 to activate the corresponding light protection function, so as to achieve the effect of enhancing positive emotions, inhibiting depression, and even alleviating depression. The icon S1 corresponds to the problem of poor sleep quality. Poor sleep quality includes frequent difficulty falling asleep, insomnia, insufficient deep sleep, and insufficient total sleep hours (easy to wake up). The user U1 can press the icon S1 to activate the corresponding light protection function (for example, including the acquisition, storage, calculation and analysis of physiological data, as well as the light step), so as to achieve the effect of improving the quality of sleep. Icon S2 corresponds to the problem of Delayed Sleep Phase Disorder (DSPD). Delayed sleep phase disorders include the inability to fall asleep before 2 am and the inability to get up normally in the morning, and the release of melatonin (Dim Light Melatonin Onset, DLMO) under dim light. The user U1 can press the icon S2 to activate the corresponding light protection function, so as to achieve the effect of alleviating the sleep phase delay disorder. Icon S3 corresponds to the problem of Advanced Sleep Phase Disorder (ASPD). Sleep phase advancement disorders include the problems of wanting to go to bed at 6 pm and waking up at about 2 pm and then having difficulty staying asleep until morning and DLMO. The user U1 can press the icon S3 to activate the corresponding light protection function, so as to achieve the effect of alleviating the sleep phase advance obstacle. The icon S4 corresponds to the problem of difficulty falling asleep. The user U1 can press the icon S4 to activate the corresponding light protection function, so as to achieve the effect of promoting drowsiness.
應說明的是,使用者待改善的狀態的種類及數量可依實際需求改變,而不以圖5所顯示的為限。It should be noted that the type and quantity of the state to be improved by the user can be changed according to actual needs, and is not limited to that shown in FIG. 5.
請參照圖1,光源裝置14與處理器12耦接,且光源裝置14依據所述至少一光參數PM輸出光LB,其中光束LB中的綠光或藍光佔光束LB的40%以上。舉例來說,光源裝置14可包括至少一個紅光發光元件、至少一個綠光發光元件、至少一個藍光發光元件以及至少一個黃光發光元件,以混合出所需的白光。發光元件例如是發光二極體,但不以此為限。藉由調整白光中特定單色光(如綠光以及藍光的其中至少一個)的佔比(如綠光/藍光的光強度與白光的光強度的比值),可令使用者產生特定的生理反應及生物效應,從而達到情緒狀態及/或睡眠狀態的調整、改善或保健的效果。在一實施例中,光源裝置14可以是單色光發光元件搭配螢光粉或單色光發光元件搭配量子點,以混合出白光。或者,光源裝置14也可以是其他種類的白光光源搭配濾光模組(包括濾光片)。1, the
圖6A至圖6D分別是光源裝置的四種示意圖。請參照圖6A,圖1的光源裝置14可以是如圖6A所示適於提供較大照明範圍的燈具14A,如日光燈或檯燈等。在此架構下,燈具14A所提供的光束LB較佳為白光,且白光依光源應用目的調整為最適光源配方(如綠光佔比、藍光佔比以及演色性範圍等)。如此,可在達到情緒狀態及/或睡眠狀態的調整、改善或保健的同時,將使用者或位於同一空間中的其他人的不適感或干擾降低至可接受或未察覺的程度。此外,採用固定式的燈具14A的架構下,使用者U1可自行選擇放置燈具14A的場所,而不一定需要去診所或醫院才能進行光照護。6A to 6D are four schematic diagrams of the light source device respectively. Please refer to FIG. 6A. The
請參照圖6B,圖1的光源裝置14可以是如圖6B所示的在經界定範圍內提供照明的艙體14B。艙體14B中設置有發光元件140B,以提供光束LB。Please refer to FIG. 6B. The
請參照圖6C,圖1的光源裝置14可以是如圖6C所示的可攜式光源裝置14C,以便於使用者U1攜帶。如此,使用者U1無論在何處都可進行光照護。Please refer to FIG. 6C. The
請參照圖6D,圖1的光源裝置14可以是如圖6D所示的穿戴式光源裝置14D。穿戴式光源裝置14D中的發光元件140D可藉由固定元件142D架設在使用者的眼睛周圍且使發光元件140D所發出的光束LB不至於大幅影響使用者的視線,以降低發光元件140D所發出的光束LB對於使用者的視覺以及心理的影響。如此,便可單純考慮光束LB對使用者LB所造成的生理效應(泛指一般生理反應,如心律及腦電反應等)及生物效應(泛指荷爾蒙分泌的改變,荷爾蒙可包括褪黑激素(melatonin)、γ-氨基丁酸(GABA)、可體松(cortisol)、多巴胺(Dopamine)、血清素(Serotonin)、正腎上腺素(norepinephrine)、腦內啡(endorphin)、催產素(Oxytocin)及乙醯膽鹼(acetylcholine))。在此情況下,光束LB可以不是白光。舉例來說,光源裝置14D中的發光元件140D可以不包括紅光發光元件,而只包括綠光發光元件以及藍光發光元件的其中至少一種。此外,採用穿戴式光源裝置的架構下,使用者無論在何處都可進行光照護。Please refer to FIG. 6D. The
請參照圖1,依據不同的需求,光照護系統1可進一步包括其他元件及/或裝置。舉例來說,光照護系統1可進一步包括雲端資料庫16。雲端資料庫16可與生理感測裝置10以及處理器12耦接,以儲存使用者的生理數據BD以及使用過的光參數PM。Please refer to FIG. 1, according to different requirements, the
醫生U2以及使用者U1可根據儲存於雲端資料庫16的生理數據BD判斷使用者U1的情緒狀態及/或睡眠狀態是否有改善。此外,醫生U2可基於儲存於雲端資料庫16的生理數據BD進行診斷,並據此調整最適光源配方(如綠光佔比、藍光佔比以及演色性範圍等)。另外,在使用者U1的授權下,使用者U1的家人U3也可觀看儲存於雲端資料庫16的生理數據BD,從而知曉使用者U1的情緒狀態及/或睡眠狀態,並即時傳遞關懷的訊息。The doctor U2 and the user U1 can determine whether the emotional state and/or sleep state of the user U1 has improved based on the physiological data BD stored in the
圖7是依照本揭露的一實施例的一種光照護方法的流程圖。請參照圖7,在步驟710中,獲取使用者的生理數據。舉例來說,可利用前述的腦波感測裝置、心電感測裝置、動態感測裝置、呼吸感測裝置或以上至少兩種的組合來獲取腦電、心律、心率變異分析、身體位置變化量、呼吸頻率或以上至少兩種的組合。Fig. 7 is a flow chart of a method for light protection according to an embodiment of the present disclosure. Referring to FIG. 7, in
在步驟720中,依據生理數據獲取對應生理數據的至少一光參數。進一步來說,可依據生理數據判斷使用者的情緒狀態及/或睡眠狀態,再確認對應的最適光源配方(如照光持續時間、照光時機、照光種類、綠光佔比、藍光佔比、演色性或以上至少兩種的組合)。In
在步驟730中,依據所述至少一光參數輸出光束,其中光束中的綠光或藍光佔光束的40%以上。進一步來說,藉由調整白光中特定單色光(如綠光以及藍光的其中至少一個)的佔比,可令使用者產生特定的生理反應及生物效應,從而達到情緒狀態及/或睡眠狀態的調整、改善或保健的效果。In
以情緒狀態為例,可依據心率變異分析判斷使用者的情緒狀態。表三條列出使用者的情緒問題、改善目標、判斷指標以及最適光源配方。在表三中,只要滿足判斷指標的其中至少一個,則可藉由對應的最適光源配方來改善情緒問題。當使用者的情緒問題不只一種時,處理器可運算出對應的最適光源配方(例如最適光源配方的聯集)來同時改善多種情緒問題。在最適光源配方中,照光持續時間、光源種類(單光或混光)以及演色性是整體一起考量,其中光源種類的單光與混光是擇其一進行光照護。以容易疲勞的問題為例,當選擇單光進行光照護時,圖1中的光束LB是綠光,且光束LB中的綠光佔光束LB的100%。另一方面,當選擇混光進行光照護時,圖1中的光束LB是白光,且光束LB中的綠光佔光束LB的40%以上。
以睡眠狀態為例,可依據腦電、心律、心率變異分析、身體位置變化量、呼吸頻率或以上至少兩種的組合判斷使用者的睡眠狀態。觀察睡眠狀態時的量測項目可包括入睡時間、起床時間、深層睡眠時間、每晚醒來次數、總睡眠時間(Total Sleep Time, TST)、睡眠效率(Sleep Efficiency, SE)及/或睡眠潛伏期(sleep latency)等,但不以此為限。此處,睡眠效率=(實際睡著時間/躺在床上總時間)*100%。睡眠潛伏期定義為躺下到入睡的時間。Taking the sleep state as an example, the user's sleep state can be determined based on brain electricity, heart rhythm, heart rate variability analysis, body position change, breathing rate, or a combination of at least two of the above. The measurement items when observing the sleep state can include time to fall asleep, time to wake up, time to deep sleep, number of awakenings per night, total sleep time (TST), sleep efficiency (SE) and/or sleep latency (sleep latency) etc., but not limited to this. Here, sleep efficiency=(actual time asleep/total time lying in bed)*100%. Sleep latency is defined as the time from lying down to falling asleep.
舉例來說,可藉由動態感測元件(如腕動計)觀察使用者每晚醒來次數,且可藉由ECG及/或EEG觀察使用者的入睡狀況。具體地,使用者的最大心律在清醒狀態下等於208-(0.7*使用者的年齡),且當使用者入睡時,使用者的最大心律會降低14 bpm(超過60歲的使用者)至24 bpm(年輕人)。人在睡覺時,LF/HF的比值會逆轉,也就是HF較高,比值低於1,若是睡覺時LF/HF的比值仍大於1,則難以深眠。因此,可藉由觀察使用者的最大心律判斷使用者是否入睡,並據此計算入睡時間、起床時間、每晚醒來次數、總睡眠時間、睡眠效率及/或睡眠潛伏期等。另一方面,使用者的腦波指標會隨不同睡眠階段(如清醒時、非快速動眼期及快速動眼期)而改變,因此可藉由觀察大腦皮層上不同區域(如區域C3、區域C4、區域O1)的腦波指標(如δ波、θ波、α波、β波)來計算使用者的深層睡眠時間。For example, the number of times the user wakes up every night can be observed by a dynamic sensing element (such as a wrist monitor), and the sleep state of the user can be observed by ECG and/or EEG. Specifically, the user’s maximum heart rate is equal to 208-(0.7*user’s age) in the awake state, and when the user falls asleep, the user’s maximum heart rate will drop by 14 bpm (for users over 60 years old) to 24 bpm (young people). When a person sleeps, the ratio of LF/HF will reverse, that is, HF is higher and the ratio is lower than 1. If the ratio of LF/HF is still greater than 1, it is difficult to sleep deeply. Therefore, it is possible to determine whether the user falls asleep by observing the user's maximum heart rhythm, and then calculate the time to fall asleep, time to wake up, number of awakenings per night, total sleep time, sleep efficiency, and/or sleep latency. On the other hand, the user’s brainwave indicators will change with different sleep stages (such as waking, non-rapid eye movement, and rapid eye movement). Therefore, you can observe different areas on the cerebral cortex (such as area C3, area C4, Area O1) brain wave indicators (such as delta wave, theta wave, alpha wave, beta wave) to calculate the user's deep sleep time.
在一實施例中,可連續七日觀察使用者的睡眠狀態,再經由這七日的睡眠狀態來確定最適光源配方。換句話說,第X天的最適光源配方是由第X-1天至第X-7天的睡眠狀態決定,但不以此為限。舉例來說,如果想促進睡意,可以直接採用對應的最適光源配方進行光照護。In one embodiment, the sleep state of the user can be observed for seven consecutive days, and then the optimal light source formula can be determined based on the sleep state of these seven days. In other words, the optimal light source formula on day X is determined by the sleep state from day X-1 to day X-7, but it is not limited to this. For example, if you want to promote drowsiness, you can directly use the corresponding optimal light source formula for light protection.
表四條列出使用者的睡眠問題、改善目標、判斷指標以及最適光源配方。在表四中,只要滿足判斷指標的其中至少一個,則可藉由對應的最適光源配方來改善睡眠問題。當使用者的睡眠問題不只一種時,或是當使用者患有睡眠及情緒問題時,處理器可運算出對應的最適光源配方(例如最適光源配方的聯集)來同時改善多種問題。在最適光源配方中,照光時機、照光持續時間、光源種類(單光或混光)以及演色性是整體一起考量,其中光源種類的單光與混光是擇其一進行光照護。
在表三及表四中,當採用混光的方式進行光照護時,白光中的單色光佔比會影響白光的色溫及所述單色光進入使用者的眼睛中的輻照度。此外,經由人因實驗可知,在不同色溫-照度的組合下,使用者會有不同的視覺與心理感受,如“刺眼的與不刺眼的”、“緊張的與放鬆的”、“困倦的與清醒的”、“憂鬱的與愉悅的”、“不舒適的與舒適的”以及“寒冷的與溫暖的”等,但不以此為限。據此,可將使用者的視覺與心理感受納入考量,調整最適光源配方中的色溫及照度。In Tables 3 and 4, when the light mixing method is used for light protection, the proportion of the monochromatic light in the white light will affect the color temperature of the white light and the irradiance of the monochromatic light into the eyes of the user. In addition, human experiments show that under different color temperature-illuminance combinations, users will have different visual and psychological feelings, such as "dazzling and non-dazzling", "tension and relaxation", "sleepy and drowsy". Sober", "Melancholic and pleasant", "Uncomfortable and comfortable" and "Cold and warm", but not limited to this. According to this, the user's visual and psychological feelings can be taken into consideration, and the color temperature and illuminance in the most suitable light source formula can be adjusted.
在光對人體的生物效應部分,透過實驗蒐集與分析人在紅色、藍色、綠色等單色光及一般照明用T5燈管的冷白光照射60分鐘前後,血液中睡眠相關的荷爾蒙(如:褪黑激素與血清素)及情緒相關荷爾蒙(如:γ-氨基丁酸、可體松、多巴胺、正腎上腺素、腦內啡、催產素與乙醯膽鹼)之變化量,並建立光源對各荷爾蒙的作用光譜(Action spectrum)。圖8是血清素的濃度改變量與光波長的關係圖。根據使用者之情況,可參考圖8選擇適當的波長對使用者進行光照,但不以此為限。In the part of the biological effects of light on the human body, through experiments to collect and analyze human sleep-related hormones (such as: Melatonin and serotonin) and mood-related hormones (such as: gamma-aminobutyric acid, cortisone, dopamine, norepinephrine, endorphin, oxytocin and acetylcholine) changes, and establish a light source pair Action spectrum of each hormone. Fig. 8 is a graph showing the relationship between the change in the concentration of serotonin and the wavelength of light. According to the user's situation, an appropriate wavelength can be selected to illuminate the user with reference to FIG. 8, but it is not limited to this.
另外,可將使用者的生物效應一併納入考量,建立可讓使用者同時滿足視覺、心理、生理及生物效應之需求的最適化色溫、照度及頻譜組合光源。舉例來說,可先基於生理效應以及生物效應確認照射光之波長與強度的可行範圍,再基於視覺效應(視覺舒適度)以及心理效應(心理愉悅)確認色溫與照度的可行範圍。所述生理效應可包括(但不限於):藍光的照射會使Ln(F4)-Ln(F3)>0,其中Ln(F4)為使用者的額葉區中的區域F4、區域F8、區域Fp2(參見圖3)的α波或θ波功率的自然對數,且Ln(F3)為使用者的額葉區中的區域F3、區域F7、區域Fp1(參見圖3)的α波或θ波功率的自然對數。所述生物效應可包括(但不限於):綠光的照射會增加血清素的分泌。In addition, the user's biological effects can be taken into consideration, and an optimal color temperature, illuminance, and spectrum combination light source that can meet the needs of the user's visual, psychological, physiological and biological effects at the same time can be established. For example, the feasible range of wavelength and intensity of the irradiated light can be confirmed based on the physiological effect and biological effect, and then the feasible range of color temperature and illuminance can be confirmed based on the visual effect (visual comfort) and psychological effect (psychological pleasure). The physiological effects may include (but are not limited to): the irradiation of blue light will make Ln(F4)-Ln(F3)>0, where Ln(F4) is the area F4, area F8, area in the frontal area of the user The natural logarithm of the power of the alpha wave or theta wave of Fp2 (see Figure 3), and Ln(F3) is the alpha wave or theta wave of the area F3, area F7, and area Fp1 (see Figure 3) in the frontal lobe of the user Natural logarithm of power. The biological effects may include (but are not limited to): green light irradiation will increase the secretion of serotonin.
在一實施例中,舒壓的最適光源配方可以是將表三中的「混光:綠光佔白光的40%以上,且藍光佔白光的5%以下」改成「混光:白光的色溫落在3000 K至4500 K的範圍內,白光的照度落在400 lux至800 lux的範圍內,且綠光進入使用者的眼睛中的輻照度(強度)≥ 30 μW/cm2 」。In one embodiment, the most suitable light source formula for stress relief can be to change the "mixed light: green light accounts for more than 40% of white light, and blue light accounts for less than 5% of white light" in Table 3 to "mixed light: the color temperature of white light. In the range of 3000 K to 4500 K, the illuminance of white light falls in the range of 400 lux to 800 lux, and the irradiance (intensity) of green light entering the user's eyes is ≥ 30 μW/cm 2 ”.
在一實施例中,提振精神及/或提升活力的最適光源配方可以是將表三中的「混光:綠光佔白光的40%以上」改成「混光:白光的色溫落在4500 K至6500 K的範圍內,白光的照度≥700 lux,綠光進入使用者的眼睛中的輻照度(強度)≥ 30 μW/cm2 ,藍光進入使用者的眼睛中的輻照度(強度)≥ 30 μW/cm2 ,且綠光的輻照度大於藍光的輻照度」。In one embodiment, the most suitable light source formula for boosting energy and/or boosting vitality can be to change the "mixed light: green light accounts for more than 40% of white light" in Table 3 to "mixed light: the color temperature of white light falls at 4500 In the range of K to 6500 K, the illuminance of white light is ≥700 lux, the irradiance (intensity) of green light entering the user’s eyes is ≥ 30 μW/cm 2 , and the irradiance (intensity) of blue light entering the user’s eyes is ≥ 30 μW/cm 2 , and the irradiance of green light is greater than that of blue light.”
在一實施例中,提升注意力的最適光源配方可以是將表三中的「混光:綠光佔白光的40%以上,且紅光佔白光的10%以上」改成「混光:白光的色溫落在4500 K至6500 K的範圍內,白光的照度≥700 lux,綠光進入使用者的眼睛中的輻照度(強度)≥ 30 μW/cm2 ,藍光進入使用者的眼睛中的輻照度(強度)≥ 30 μW/cm2 ,且綠光的輻照度大於藍光的輻照度」。In one embodiment, the most suitable light source formula for enhancing attention can be to change the "mixed light: green light accounts for more than 40% of white light, and red light accounts for more than 10% of white light" in Table 3 to "mixed light: white light The color temperature falls within the range of 4500 K to 6500 K, the illuminance of white light is ≥700 lux, the irradiance (intensity) of green light entering the user’s eyes is ≥ 30 μW/cm 2 , the radiation of blue light entering the user’s eyes Illuminance (intensity) ≥ 30 μW/cm 2 , and the irradiance of green light is greater than that of blue light”.
在一實施例中,讓使用者心情愉悅、抑制負面情緒及/或提升正向情緒的最適光源配方可以是將表三中的「綠光佔白光的40%以上,且藍光佔白光的10%以上」改成「混光:白光的色溫落在4500 K至6500 K的範圍內,白光的照度≥700 lux,且藍光進入使用者的眼睛中的輻照度(強度)≥ 30 μW/cm2 」。In one embodiment, the most suitable light source formula for making users happy, suppressing negative emotions, and/or enhancing positive emotions may be “green light accounts for more than 40% of white light, and blue light accounts for 10% of white light. "Above" is changed to "Mixed light: the color temperature of white light falls within the range of 4500 K to 6500 K, the illuminance of white light is ≥700 lux, and the irradiance (intensity) of blue light entering the user’s eyes ≥ 30 μW/cm 2 ” .
在一實施例中,改善睡眠品質的最適光源配方可以是將表四中的「混光:綠光佔白光的40%以上」改成「混光:白光的色溫≥5000 K,白光的照度≥700 lux,綠光進入使用者的眼睛中的輻照度(強度)≥ 30 μW/cm2 ,且藍光進入使用者的眼睛中的輻照度(強度)≥ 30 μW/cm2 」。In one embodiment, the most suitable light source formula to improve sleep quality can be to change the "mixed light: green light accounts for more than 40% of white light" in Table 4 to "mixed light: white light color temperature ≥ 5000 K, white light illuminance ≥ 700 lux, the irradiance (intensity) of green light entering the user’s eyes is ≥ 30 μW/cm 2 , and the irradiance (intensity) of blue light entering the user’s eyes is ≥ 30 μW/cm 2 ”.
在一實施例中,緩解DSPD的最適光源配方可以是將表四中的「混光:綠光佔白光的40%以上」改成「混光:白光的色溫≥5000 K,白光的照度≥700 lux,綠光進入使用者的眼睛中的輻照度(強度)≥ 30 μW/cm2 ,且藍光進入使用者的眼睛中的輻照度(強度)≥ 30 μW/cm2 」。In one embodiment, the most suitable light source formula to alleviate DSPD can be to change the "mixed light: green light accounts for more than 40% of white light" in Table 4 to "mixed light: white light color temperature ≥ 5000 K, white light illuminance ≥ 700 lux, the irradiance (intensity) of green light entering the user's eyes is ≥ 30 μW/cm 2 , and the irradiance (intensity) of blue light entering the user's eyes is ≥ 30 μW/cm 2 ”.
在一實施例中,緩解ASPD的最適光源配方可以是將表四中的「混光:藍光佔白光的40%以上」改成「混光:白光的色溫≥5000 K,白光的照度≥800 lux,且藍光進入使用者的眼睛中的輻照度(強度)≥ 30 μW/cm2 」。In one embodiment, the most suitable light source formula to alleviate ASPD can be to change the "mixed light: blue light accounts for more than 40% of white light" in Table 4 to "mixed light: white light color temperature ≥ 5000 K, white light illuminance ≥ 800 lux , And the irradiance (intensity) of blue light entering the user’s eyes ≥ 30 μW/cm 2 ".
在一實施例中,促進睡意的最適光源配方可以是將表四中的「混光:綠光佔白光的50%以上,且藍光佔白光的5%以下」改成「混光:白光的色溫落在3000 K至4500 K的範圍內,白光的照度≦600 lux,綠光進入使用者的眼睛中的輻照度(強度)≥ 30 μW/cm2 ,且黃光進入使用者的眼睛中的輻照度(強度)≥ 30 μW/cm2 」。In one embodiment, the most suitable light source formula to promote drowsiness can be to change the "mixed light: green light accounts for more than 50% of white light, and blue light accounts for less than 5% of white light" in Table 4 to "mixed light: the color temperature of white light. Within the range of 3000 K to 4500 K, the illuminance of white light is less than or equal to 600 lux, the irradiance (intensity) of green light entering the user’s eyes is ≥ 30 μW/cm 2 , and the irradiance of yellow light entering the user’s eyes Illuminance (intensity) ≥ 30 μW/cm 2 ".
綜上所述,本揭露的實施例的光照護系統及光照護方法可獲取使用者的生理數據、依據生理數據判斷使用者的情緒狀態及/或睡眠狀態以及依據判斷結果進行光照護。由於光照護具有較小的副作用,且光照護不易與食物產生交互作用,因此本揭露的實施例的光照護系統及光照護方法可在較小副作用且飲食較不受限的前提下改善情緒問題及/或睡眠問題。在一實施例中,光源裝置可採用可攜式光源裝置或是穿戴式光源裝置,以便於攜帶,並讓光照護的進行不受限於場地及/或空間大小。在另一實施例中,可藉由雲端資料庫儲存生理數據以及光參數,且儲存於雲端資料庫的生理數據以及光參數可經由使用者的授權分享給使用者的醫生及/或家人。在又一實施例中,還可將使用者的視覺、心理感受、生理及生物效應納入考量,調整最適光源配方中的色溫、照度及頻譜組合。In summary, the light protection system and light protection method of the embodiments of the present disclosure can obtain physiological data of the user, determine the emotional state and/or sleep state of the user according to the physiological data, and perform light protection according to the judgment result. Since light protection has less side effects and is not easy to interact with food, the light protection system and light protection method of the embodiments of the present disclosure can improve emotional problems under the premise of less side effects and less restricted diet. And/or sleep problems. In one embodiment, the light source device may be a portable light source device or a wearable light source device, which is convenient to carry, and the light protection is not limited to the size of the venue and/or space. In another embodiment, the physiological data and optical parameters can be stored in a cloud database, and the physiological data and optical parameters stored in the cloud database can be shared with the user's doctor and/or family through the user's authorization. In yet another embodiment, the user's visual, psychological, physical and biological effects can also be taken into consideration, and the color temperature, illuminance, and spectrum combination in the optimal light source formula can be adjusted.
雖然本揭露已以實施例揭露如上,然其並非用以限定本揭露,任何所屬技術領域中具有通常知識者,在不脫離本揭露的精神和範圍內,當可作些許的更動與潤飾,故本揭露的保護範圍當視後附的申請專利範圍所界定者為準。Although the present disclosure has been disclosed in the above embodiments, it is not intended to limit the present disclosure. Anyone with ordinary knowledge in the relevant technical field can make some changes and modifications without departing from the spirit and scope of this disclosure. Therefore, The scope of protection of this disclosure shall be subject to those defined by the attached patent scope.
1‧‧‧光照護系統10‧‧‧生理感測裝置10A‧‧‧腦波感測裝置10B‧‧‧心電感測裝置12‧‧‧處理器14‧‧‧光源裝置14A‧‧‧燈具14B‧‧‧艙體14C‧‧‧可攜式光源裝置14D‧‧‧穿戴式光源裝置16‧‧‧雲端資料庫140B、140D‧‧‧發光元件142D‧‧‧固定元件710、720、730‧‧‧步驟A1、A2、C3、C4、Cz、Fp1、Fp2、F3、F4、Fz、F7、F8、O1、O2、P3、P4、Pz、T3、T4、T5、T6‧‧‧區域BD‧‧‧生理數據DP‧‧‧顯示裝置E1、E2、E3、E4、S1、S2、S3、S4‧‧‧圖標LB‧‧‧光束PM‧‧‧光參數U1‧‧‧使用者U2‧‧‧醫生U3‧‧‧家人1‧‧‧
圖1是依照本揭露的一實施例的一種光照護系統的示意圖。 圖2是腦波感測裝置的一種示意圖。 圖3是獲取腦電圖(Electroencephalograph, EEG)時電極配置的示意圖。 圖4是心電感測裝置的一種示意圖。 圖5是顯示裝置的一種示意圖。 圖6A至圖6D分別是光源裝置的四種示意圖。 圖7是依照本揭露的一實施例的一種光照護方法的流程圖。 圖8是血清素的濃度改變量與光波長的關係圖。Fig. 1 is a schematic diagram of a light protection system according to an embodiment of the present disclosure. Fig. 2 is a schematic diagram of a brain wave sensing device. Fig. 3 is a schematic diagram of electrode configuration when obtaining an electroencephalogram (Electroencephalograph, EEG). Fig. 4 is a schematic diagram of a cardiogram measuring device. Fig. 5 is a schematic diagram of a display device. 6A to 6D are four schematic diagrams of the light source device respectively. Fig. 7 is a flow chart of a method for light protection according to an embodiment of the present disclosure. Fig. 8 is a graph showing the relationship between the change in the concentration of serotonin and the wavelength of light.
1‧‧‧光照護系統 1‧‧‧Light protection system
10‧‧‧生理感測裝置 10‧‧‧Physiological sensing device
12‧‧‧處理器 12‧‧‧Processor
14‧‧‧光源裝置 14‧‧‧Light source device
16‧‧‧雲端資料庫 16‧‧‧Cloud Database
BD‧‧‧生理數據 BD‧‧‧Physiological data
LB‧‧‧光束 LB‧‧‧Beam
PM‧‧‧光參數 PM‧‧‧Optical Parameters
U1‧‧‧使用者 U1‧‧‧User
U2‧‧‧醫生 Doctor U2‧‧‧
U3‧‧‧家人 U3‧‧‧Family
Claims (15)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16/232,065 US11197975B2 (en) | 2018-03-22 | 2018-12-26 | Light health care system and light health care method |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862646379P | 2018-03-22 | 2018-03-22 | |
| US62/646,379 | 2018-03-22 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201941216A TW201941216A (en) | 2019-10-16 |
| TWI734047B true TWI734047B (en) | 2021-07-21 |
Family
ID=69023379
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW107128515A TWI689752B (en) | 2018-03-22 | 2018-08-15 | Light source module, sensing device and method for generating superimposed structure pattern |
| TW107140149A TWI734047B (en) | 2018-03-22 | 2018-11-13 | Light care system and light care method |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW107128515A TWI689752B (en) | 2018-03-22 | 2018-08-15 | Light source module, sensing device and method for generating superimposed structure pattern |
Country Status (1)
| Country | Link |
|---|---|
| TW (2) | TWI689752B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI732485B (en) * | 2020-03-16 | 2021-07-01 | 大陸商廣州印芯半導體技術有限公司 | Polarization beam splitting system and method thereof |
| CN113820870B (en) | 2020-06-19 | 2024-03-29 | 三赢科技(深圳)有限公司 | Projection module, imaging module and electronic device |
| TWI799087B (en) * | 2021-05-19 | 2023-04-11 | 英屬開曼群島商大峽谷智慧照明系統股份有限公司 | Compilation method of dynamic spectrum program and human-caused lighting method thereof |
| US20240065567A1 (en) * | 2022-08-23 | 2024-02-29 | Samsung Electronics Co., Ltd. | Methods and systems for polarized photoplethysmography (ppg) and biosignal analysis |
| US12029537B2 (en) * | 2022-08-23 | 2024-07-09 | Samsung Electronics Co., Ltd | Polarized photoplethysmography (PPG) biosensors, arrays and systems |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI293887B (en) * | 2006-07-28 | 2008-03-01 | Edison Opto Corp | Light modulating system for medical treatment and health care |
| CN107439056A (en) * | 2015-04-16 | 2017-12-05 | 飞利浦灯具控股公司 | Illumination control apparatus |
| CN107596533A (en) * | 2017-07-18 | 2018-01-19 | 重庆大学 | The regulator control system and method for a kind of luminous environment |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6512385B1 (en) * | 1999-07-26 | 2003-01-28 | Paul Pfaff | Method for testing a device under test including the interference of two beams |
| JP6137179B2 (en) * | 2011-07-26 | 2017-05-31 | カール・ツァイス・エスエムティー・ゲーエムベーハー | Optical system of microlithography projection exposure apparatus and microlithography exposure method |
| CN103472457B (en) * | 2013-09-13 | 2015-06-10 | 中国科学院空间科学与应用研究中心 | Three-dimensional imaging system and method for calculating correlation flight time by means of sparse aperture compression |
| KR102178588B1 (en) * | 2016-06-30 | 2020-11-16 | 에이에스엠엘 홀딩 엔.브이. | Device and method for pupil illumination in overlay and critical dimension sensors |
-
2018
- 2018-08-15 TW TW107128515A patent/TWI689752B/en active
- 2018-11-13 TW TW107140149A patent/TWI734047B/en active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI293887B (en) * | 2006-07-28 | 2008-03-01 | Edison Opto Corp | Light modulating system for medical treatment and health care |
| CN107439056A (en) * | 2015-04-16 | 2017-12-05 | 飞利浦灯具控股公司 | Illumination control apparatus |
| CN107596533A (en) * | 2017-07-18 | 2018-01-19 | 重庆大学 | The regulator control system and method for a kind of luminous environment |
Also Published As
| Publication number | Publication date |
|---|---|
| TW201940929A (en) | 2019-10-16 |
| TW201941216A (en) | 2019-10-16 |
| TWI689752B (en) | 2020-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI734047B (en) | Light care system and light care method | |
| US20210268226A1 (en) | Stress reduction and sleep promotion system | |
| US11197975B2 (en) | Light health care system and light health care method | |
| Cahn et al. | Meditation (Vipassana) and the P3a event-related brain potential | |
| Plitnick et al. | The effects of red and blue light on alertness and mood at night | |
| Askaripoor et al. | Non-image forming effects of light on brainwaves, autonomic nervous activity, fatigue, and performance | |
| CN108078565A (en) | A kind of sleep monitor feedback and the automatic improvement device of sleep | |
| Scheuermaier et al. | Improved cognitive morning performance in healthy older adults following blue-enriched light exposure on the previous evening | |
| AU2024204146A1 (en) | Stress Reduction And Sleep Promotion System | |
| Ross et al. | The impact of modulated, colored light on the autonomic nervous system | |
| Wang et al. | Effects of lighting on ECG, visual performance and psychology of the elderly | |
| WO2019082180A1 (en) | An electrical stimulation device and methods of using the device | |
| JP2019523660A (en) | Frontal head cooling method and apparatus for stimulating parasympathetic nervous system for treatment of insomnia | |
| Laufer et al. | Psychophysiological effects of coloured lighting on older adults | |
| KR20230051194A (en) | Methods and systems for measuring anxiety levels associated with and/or correlated with modified state of consciousness levels and/or pain levels | |
| TWI815564B (en) | Sleep-assistance system and sleep-assistance method | |
| TWI713806B (en) | Light source apparatus and wearable apparatus | |
| Figueiro et al. | Sleep opportunities and periodic light exposures: impact on biomarkers, performance and sleepiness | |
| Reddy et al. | An experimental study of the effects on participants of the one-week Ashram based YPV Arhat Yoga Intensive Program on their BMI, energy and stress levels, brain wave activity and heart rate variability (HRV) | |
| KR20230158655A (en) | Apparatus for controlling biological functions by light stimulation and method of operating the same | |
| US20250050056A1 (en) | System for providing sleep healthcare service using artificial intelligence-based brainwave entrainment and autonomic nervous system control | |
| Chandra et al. | Assessment of EEG Sub-Band Spectral Changes Induced by Lu10 Acupressure Application | |
| JP2695142B2 (en) | Relaxation induction device and learning method using the same | |
| RU2780128C1 (en) | Device for audiovisual cortex stimulation | |
| Weng et al. | Psychological and physiological influences of CCTs on young people before sleep |